Tickernomics

10y

Historical Returns*:

SPY

27.80%

BNTX

7.61%

SPY

32.66%

-51.58%

BNTX

SPY

108.59%

BNTX

258.75%

SPY

302.52%

BNTX

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

27655.74

9266.64

0.33

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-52.76

8.52

1.30

3.60

0.00

-6.66

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

0.84

85.63

-46.13

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

4.4672

-7.51

-7.05

0.04

Other Earnings and Cash Flow Stats:

BioNTech SE ( BNTX ) Net Income TTM ($MM) is -524.18

BioNTech SE ( BNTX ) Operating Income TTM ($MM) is -1036.72

BioNTech SE ( BNTX ) Owners' Earnings Annual ($MM) is 0.00

BioNTech SE ( BNTX ) Current Price to Owners' Earnings ratio is 0.00

BioNTech SE ( BNTX ) EBITDA TTM ($MM) is -809.53

BioNTech SE ( BNTX ) EBITDA Margin is -46.13%

Capital Allocation:

BioNTech SE ( BNTX ) has paid 0.00 dividends per share and bought back -2.692991 million shares in the past 12 months

BioNTech SE ( BNTX ) has increased its debt by 71.344425914863 million USD in the last 12 months

Capital Structure:

BioNTech SE ( BNTX ) Interest-bearing Debt ($MM) as of last quarter is 272

BioNTech SE ( BNTX ) Annual Working Capital Investments ($MM) are 954

BioNTech SE ( BNTX ) Book Value ($MM) as of last quarter is 21347

BioNTech SE ( BNTX ) Debt/Capital as of last quarter is 1%

Other Balance Sheet Stats:

BioNTech SE ( BNTX ) has 10748 million in cash on hand as of last quarter

BioNTech SE ( BNTX ) has 2817 million of liabilities due within 12 months, and long term debt 272 as of last quarter

BioNTech SE ( BNTX ) has 244 common shares outstanding as of last quarter

BioNTech SE ( BNTX ) has 0 million USD of preferred stock value

Academic Scores:

BioNTech SE ( BNTX ) Altman Z-Score is 6.46 as of last quarter

BioNTech SE ( BNTX ) Piotroski Score is 3.00 as of last quarter

Corporate Governance:

BioNTech SE ( BNTX ) largest shareholder is owning shares at 0.00 ($MM) value

(an insider) shares of BioNTech SE ( BNTX ) for the amount of $ on

69.58% of BioNTech SE ( BNTX ) is held by insiders, and 23.06% is held by institutions

BioNTech SE ( BNTX ) went public on 2019-10-10

About BioNTech SE ( BNTX ) :

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.